Endo Launches First US Rival To Merz’s Cuvposa
Company’s Par Unit Starts Shipping Glycopyrrolate Oral Solution
Endo’s Par Pharmaceutical has begun shipping the first generic version of Merz’s Cuvposa (glycopyrrolate) 1mg/5ml oral solution in the US following FDA approval.
You may also be interested in...
Endo still sees significant potential in Vasostrict despite the onset of competition. Meanwhile, the firm says it is focusing on “optimizing” its generics business.
Viatris has voluntarily recalled one batch of its Semglee (insulin glargine) pre-filled pens due to the potential for the label to be missing on some pre-filled pens within a labelled carton. The company said that it will arrange for the return of all recalled products.
Amneal’s president and co-CEO, Chirag Patel, has shared the company’s long-term plan of becoming one of the top biosimilars players in the US. The company is set to launch three biosimilars this year, while building its manufacturing capabilities and looking for opportunities and partnerships.